Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Singapore’s TauRx Faces U.S. Delays With Alzheimer’s Drug Plans

This article was originally published in PharmAsia News

Executive Summary

Recent reports that Alzheimer's drug Rember (methylthionium) of Singapore's TauRx would head into Phase III trials soon for U.S. approval in the wake of favorable Phase II trials may have been premature. It turns out the company has not filed an IND application in the United States and has not completed any large-species toxicology studies. TauRx Chairman Claude Wischik said he hoped both the studies could be done in parallel with an IND review. He added that the U.S. trials would be conducted with a different formulation than the one that just cleared Phase II trials in the United Kingdom and Singapore. (Click here for more

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts